Evaluating Enhanced Recovery After Surgery ERAS for Faster Recovery Following Minimally Invasive Gastrectomy in Adults with Gastric Cancer

What this Trial Is About

Researchers are evaluating the impact of an Enhanced Recovery After Surgery ERAS protocol on recovery following minimally invasive gastrectomy in adults with gastric cancer. This prospective, randomized, open-label, multicenter study compares the ERAS protocol to conventional perioperative care to see if more patients meet discharge criteria earlier after surgery. The study aims to improve post-surgery recovery and reduce hospital stays by using evidence-based practices. Participants are randomly assigned to either the ERAS group or the conventional care group. The ERAS protocol includes preoperative carbohydrate loading, shorter fasting periods, multimodal opioid-sparing pain relief, early removal of drains and intravenous lines, early mobilization, and prevention of nausea and vomiting. The conventional group receives the current standard care at the institution. Both groups undergo minimally invasive gastrectomy, either laparoscopic or robotic. During the study, patients are monitored for meeting discharge criteria at 900 AM on postoperative day 4. Researchers also assess pain levels, gastrointestinal function, nausea and vomiting, quality of recovery using the EQ-5D-5L questionnaire, and major postoperative complications up to 30 days after surgery. Patients provide feedback through questionnaires, and their health is closely followed to evaluate the benefits of the ERAS protocol compared to conventional care.

Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy